Linkedin Facebook Contact with Pharma Industrial India
 

Last edition

november-december, 2024
All magazines
Subscribe to our magazine
autodoc
 
Home › News › Quality / GMP

Concord Biotech Limited receives EIR for Unit III

Concord Biotech Limited receives EIR for Unit III

Concord Biotech Limited has announced that the United States Food and Drug Administration (USFDA) had conducted an inspection at Company's Manufacturing Unit III, Plot No. 84 And 668, Ranasar and Malawada, Limbasi Sojitra Road, Near Limbasi, Taluka- Matar, Kheda, Gujarat from Monday, 26th June, 2023 to Friday 30th June, 2023.

Pursuant to the above inspection by United States Food and Drug Administration (USFDA), the Company has now received the Establishment Inspection Report (EIR) indicating closure of inspection and classifying the facility as "no action indicated" ("NAI").

Based on this inspection and the USFDA NAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP).
Read more on:
CGMP Concord Biotech EIR NAI USFDA
More news about: quality / gmp | Published by Sudeep Soparkar | August - 23 - 2023 | 537

Last news about this category

LGM Pharma Expands Analytical Testing Services with New Services LGM Pharma Expands Analytical Testing Services with New Services
Avery Dennison Rolls Out AD Minidose U9XM to Ensure Authenticity of Pharma Devices Avery Dennison Rolls Out AD Minidose U9XM to Ensure Authenticity of Pharma Devices
eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
Gritgen Therapeutics Launches Operations at Commercial GMP Facility in China Gritgen Therapeutics Launches Operations at Commercial GMP Facility in China
Aurisco's Manufacturing Site in China Clears FDA Inspection Aurisco's Manufacturing Site in China Clears FDA Inspection
Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC) Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC)
Successful FDA inspection at Auriscos manufacturing site in Yangzhou, China Successful FDA inspection at Auriscos manufacturing site in Yangzhou, China
Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
Dr. Reddys API plant in Hyderabad gets EIR from U.S. FDA Dr. Reddys API plant in Hyderabad gets EIR from U.S. FDA
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members

Privacy Policy | Cookies Policy